Akums Group signed a long-term deal worth 200 million euros with a global pharma company. They will produce and supply oral liquid formulations for the European market. Commercial supply starts in 2027 and ends in 2032. Akums will receive 100 million euros upfront for product development and European site approval. European approval process for the facility will start soon.
